CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors

Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750-760. 2. Balla G, Vercellotti GM, Muller-Eberhard U, Eaton J, Jacob HS. Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. Lab Invest. 1991;64(5):648-655. 3. Kumar S, Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol Lett. 2005;157(3):175-188. 4. Gladwin MT, Ofori-Acquah SF. Erythroid DAMPs drive inflammation in SCD. Blood. 2014;123(24):3689-3690. 5. Belcher JD, Chen C, Nguyen J, et al. Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: role of heme oxygenase-1 induction. PLoS One. 2018;13(4):e0196455. 6. Wejman JC, Hovsepian D, Wall JS, Hainfeld JF, Greer J. Structure and assembly of haptoglobin polymers by electron microscopy. J Mol Biol. 1984;174(2):343-368. 7. Koda Y, Soejima M, Yoshioka N, Kimura H. The haptoglobin-gene deletion responsible for anhaptoglobinemia. Am J Hum Genet. 1998; 62(2):245-252. 8. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42(10):1589-1600. 9. Andersen CBF, Stødkilde K, Sæderup KL, et al. Haptoglobin. Antioxid Redox Signal. 2017;26(14):814-831. 10. Panter SS, Sadrzadeh SM, Hallaway PE, Haines JL, Anderson VE, Eaton JW. Hypohaptoglobinemia associated with familial epilepsy. J Exp Med. 1985;161(4):748-754. 11. Asleh R, Marsh S, Shilkrut M, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92(11):1193-1200. 12. Pechlaner R, Kiechl S, Willeit P, et al. Haptoglobin 2-2 genotype is not associated with cardiovascular risk in subjects with elevated glycohemoglobin-results from the Bruneck Study. J Am Heart Assoc. 2014;3(3):e000732. 13. Boettger LM, Salem RM, Handsaker RE, et al. Recurring exon deletions in the HP (haptoglobin) gene contribute to lower blood cholesterol levels. Nat Genet. 2016;48(4):359-366. 14. Dalan R, Liuh LG. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus. Eur J Prev Cardiol. 2018;25(14):1502-1519. 15. Carter K, Bowen DJ, McCune CA, Worwood M. Haptoglobin type neither influences iron accumulation in normal subjects nor predicts clinical presentation in HFE C282Y haemochromatosis: phenotype and genotype analysis. Br J Haematol. 2003;122(2):326-332. 16. Blackburn SL, Kumar PT, McBride D, et al. Unique contribution of haptoglobin and haptoglobin genotype in aneurysmal subarachnoid hemorrhage. Front Physiol. 2018;9:592. 17. Gaastra B, Ren D, Alexander S, et al. Haptoglobin genotype and aneurysmal subarachnoid hemorrhage: individual patient data analysis. Neurology. 2019;92(18):e2150-e2164. 18. Strunk RC, Cohen RT, Cooper BP, et al. Wheezing symptoms and parental asthma are associated with a physician diagnosis of asthma in children with sickle cell anemia. J Pediatr. 2014;164(4):821-826.e1. 19. Gaston M, Rosse WF. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol. 1982;4(2):197-201. 20. Gaston M, Smith J, Gallagher D, et al. Recruitment in the cooperative study of sickle cell disease (CSSCD). Control Clin Trials. 1987; 8(4 Suppl):131S-140S. 21. Kerchberger VE, Bastarache JA, Shaver CM, et al. Haptoglobin-2 variant increases susceptibility to the acute respiratory distress syndrome during sepsis. JCI Insight. 2019;4(21):131206. 22. Soejima M, Koda Y. TaqMan-based real-time PCR for genotyping common polymorphisms of haptoglobin (HP1 and HP2). Clin Chem. 2008;54(11):1908-1913. 23. Adekile AD, Haider MZ. Haptoglobin gene polymorphisms in sickle cell disease patients with different βS-globin gene haplotypes. Med Princ Pract. 2010;19(6):447-450. 24. Quinn CT, Lee NJ, Shull EP, Ahmad N, Rogers ZR, Buchanan GR. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood. 2008;111(2):544-548. 25. McClish DK, Smith WR, Levenson JL, et al. Comorbidity, pain, utilization, and psychosocial outcomes in older versus younger sickle cell adults: the PiSCES project. Biomed Res Int. 2017;2017:4070547. 26. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37-47. 27. Levy AP, Hochberg I, Jablonski K, et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J Am Coll Cardiol. 2002;40(11):1984-1990. 28. Beeri MS, Lin H-M, Sano M, et al. Association of the haptoglobin gene polymorphism with cognitive function and decline in elderly African American adults with type 2 diabetes findings from the action to control cardiovascular risk in diabetes – memory in diabetes (ACCORD-MIND) study. JAMA Netw Open. 2018;1(7):1-11.